Peer-reviewed veterinary case report
Stem cell treatment improves pelvic limb function in dogs with spinal
By Jung, Dong-In et al.·Published in Journal of the neurological sciences·2009·Department of Veterinary Internal Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury.
- Species:
- dog
Plain-English summary
A group of 30 Beagle dogs with spinal cord injuries received either their own stem cells (autologous) or stem cells from other dogs (allogenic) to see which treatment helped them recover better. Both groups showed improvement in their ability to use their back legs compared to dogs that did not receive any stem cells. While the dogs that received their own stem cells had better results overall, those that received stem cells from other dogs also experienced some recovery. This suggests that both types of stem cell treatments could be helpful for dogs with spinal cord injuries.
People also search for: dog spinal cord injury treatment · Beagle stem cell therapy · dog back leg weakness recovery
Abstract
The purpose of this study is to compare the therapeutic effects between autologous and allogenic bone-marrow-derived mesenchymal stem cell (MSC) transplantation in experimentally-induced spinal cord injury (SCI) of dogs. Thirty adult Beagle dogs (control group=10, autologous group=10, and allogenic group=10) were used in this study. Prelabeled MSCs were intrathecally transplanted through the lumbar spinal cord into the injured lesion at a density of 1 x 10(7) cells 7 days after SCI. Neurological signs of dogs in both autologous and allogenic groups were improved in their pelvic limbs after SCI compared with those in control group. Both autologous and allogenic groups showed significantly higher the Olby scores than control group (p<0.05). This finding was consistent with results of MRI and histopathological examination in both groups. Immunofluorescence analysis revealed that prelabeled autologous and allogenic MSCs were detected in the injured lesions both at 1 and 4 weeks after transplantation. However, the distribution ratio of MSCs on the injured lesion in allogenic group was significantly decreased at 4 weeks after transplantation relatively to at 1 week after transplantation. The mRNA expression for neurotrophic factors in both allogenic and autologous groups was significantly higher than that in control groups (p<0.05). Even though autologous MSC transplantation showed more beneficial effect than that of allogenic MSC transplantation, transplantation of allogenic MSCs also improved functional recovery following SCI. This study demonstrates that both autologous and allogenic MSC transplantation could be clinically useful therapeutic approaches for treating SCI.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19555980/